National MS Education and Awareness Month is celebrated each year in the US in March, after having been launched in 2003 by ...
Ocrelizumab significantly reduced the number and volume of cortical lesions associated with multiple sclerosis at 120 weeks, ...
Michela Luciano is a Science Writer at BioNews. Originally from the picturesque mountain town of L’Aquila, Italy, Michela ...
MS patients on anti-CD20 therapies are significantly less likely to discontinue treatment than those given other DMTs, a ...
TG Therapeutics' financial health is solid, with a market cap of $5.7bn and a strong cash position, ensuring an indefinite ...
The list price of Mavenclad is around £2,050 per 10mg tablet, although, Merck is providing it to the NHS in England at a ...
A simple treatment algorithm to aid in the selection of appropriate DMTs reduces racial disparities in patients with ...
Indirect comparisons suggest that the relapse rate with cladribine is similar to that of ocrelizumab and ofatumumab, the most commonly prescribed treatments for active RRMS. The CLARITY trial ...
as well as the performances of multiple sclerosis therapy Ocrevus (ocrelizumab) and Hemlibra (emicizumab) for haemophilia. Diagnostic led the charge, rising 24% to CHF 5.3 billion, but pharma also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback